套细胞淋巴瘤中的伊布替尼耐药:临床、分子与治疗方面
套细胞淋巴瘤(MCL)占所有B细胞淋巴瘤的约6-10%。伊布替尼是布鲁顿酪氨酸激酶(BTK)抑制剂,虽显著改善MCL患者结局,但约三分之一患者存在原发耐药,其他患者出现获得性耐药。本综述描述BCR信号通路生物学、总结促成伊布替尼获批的关键临床试验,并回顾原发与获得性耐药的分子机制及克服耐药的最新研究。
要点
- MCL约占所有B细胞淋巴瘤的6-10%。
- 伊布替尼治疗MCL中约三分之一患者为原发耐药,其他患者出现获得性耐药。
- 综述总结BCR信号通路生物学、关键临床试验及原发与获得性耐药的分子机制。
核心结论
- 理解导致原发和获得性伊布替尼耐药的分子事件对于改善MCL患者结局至关重要。
研究设计与样本
- 本综述描述BCR信号通路生物学,总结促成伊布替尼获批的关键临床试验,并回顾原发与获得性耐药的分子机制及克服耐药的最新研究。
主要发现
- 套细胞淋巴瘤(MCL)是一种淋巴增殖性疾病,约占所有B细胞淋巴瘤病例的6-10%。
- 伊布替尼是布鲁顿酪氨酸激酶(BTK)抑制剂,BTK是早期B细胞受体(BCR)信号通路的关键组分。
- 尽管伊布替尼治疗显著改善了MCL患者的结局,但约三分之一患者存在原发耐药,其他患者出现获得性耐药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder comprising about 6-10% of all B cell lymphoma cases. Ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), a key component of early B-cell receptor (BCR) signalling pathways. Although treatment with ibrutinib has significantly improved the outcome of MCL patients, approximately one-third of the patients have primary drug resistance while others appear to develop acquired resistance. Understanding the molecular events leading to the primary and acquired resistance to ibrutinib is essential for achieving better outcomes in patients with MCL. In this review, we describe the biology of the BCR signalling pathway and summarize the landmark clinical trials that have led to the approval of ibrutinib. We review the molecular mechanisms underlying primary and acquired ibrutinib resistance as well as recent studies dealing with overcoming ibrutinib resistance.
引用
- Hershkovitz-Rokah O, Pulver D, Lenz G, et al. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. Br J Haematol. 2018. PMID: 29359797. doi:10.1111/bjh.15108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。